000			nab a22 7a 4500
999			_c16832 _d16832
003			PC16832
005			20220505094639.0
008			220505b xxu||||| |||| 00| 0 eng d
040			_cH12O
041			_aeng
100			_9431 _aGrávalos Castro, Cristina _eOncología Médica
245	0	0	_aCapecitabine and irinotecan with bevacizumab 2-weekly for metastatic colorectal cancer: the phase II AVAXIRI study. _h[artículo]
260			_bBMC cancer, _c2015
300			_a15:327.
500			_aFormato Vancouver: García Alfonso P, Chaves M, Muñoz A, Salud A, García González M, Grávalos C et al; Spanish Cooperative Group for the Treatment of Digestive Tumors (TTD). Capecitabine and irinotecan with bevacizumab 2-weekly for metastatic colorectal cancer: the phase II AVAXIRI study. BMC Cancer. 2015 Apr 29;15:327.
501			_aPMID: 25925749 PMCID: PMC4423590
504			_aContiene 31 referencias
520			_aBackground: The optimal sequence of chemotherapeutic agents is not firmly established for the treatment of metastatic colorectal cancer (mCRC). This phase II multi-centre study investigated the efficacy and tolerability of a standard capecitabine plus irinotecan (XELIRI) regimen with bevacizumab in previously untreated patients with mCRC. Methods: Patients received intravenous irinotecan 175 mg/m(2) on day 1 and oral capecitabine 1000 mg/m(2) (800 mg/m(2) for patients >65 years of age) twice daily on days 2-8, followed by a 1-week rest, and bevacizumab 5 mg/kg as an intravenous infusion on day 1 every 2 weeks. Results: Seventy-seven patients were included in the intention-to-treat and safety populations. Progression-free survival at 9 months was 61%. The overall response and disease control rates were 51% and 84%, respectively. Median progression-free and overall survival times were 11.9 and 24.8 months, respectively. 48 patients (62%) had at least one grade 3/4 adverse event, the most common being asthenia, diarrhoea and neutropenia. Quality of life varied little over the study period with mean visual analogue scale general health scores ranging from 71 to 76 over cycles 1-11. Conclusion: Our study found irinotecan and capecitabine administered fortnightly with bevacizumab in patients with mCRC to be an effective and tolerable regimen.
710			_9303 _aServicio de Oncología Médica
856			_uhttp://pc-h12o-es.m-hdoct.a17.csinet.es/pdf/pc/1/pc16832.pdf _ySolicitar documento
942			_2ddc _cART _n0